CURRENT REPORT 28/2024
September 10, 2024

Continuation of the development of PRMT5 program

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow („**Company**"), hereby informs that on September 9, 2024, based on the results of works on MTA-cooperative PRMT5 inhibitors, which showed best-in-class potential, favorable drug-like properties and effective PRMT5 inhibition dependent on MTA binding and taking into the account that:

- Ryvu PRMT5 inhibitors showed robust antiproliferative effects on a range of MTAP-deleted cell lines, providing a good safety window for MTAP WT cells;
- Further characterization did not reveal any significant liabilities;
- Compounds showed an excellent correlation between compound exposure and on-target effect in PK/PD studies and very good efficacy in in vivo xenograft models;

it has decided to advance Ryvu's potentially best-in-class PRMT5 inhibitor RVU305 to further steps of preclinical development, including toxicology and API/IMP manufacturing, targeting IND/CTA filing in H2 2025.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Article 17.1 of MAR

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice-president of the Management Board